Retatrutide in Pennsylvania (2026)
retatrutide · GLP-1 weight management · Pennsylvania
About Retatrutide
Investigational triple agonist (GLP-1 / GIP / glucagon). Phase 3 weight loss approached ~24%, the highest yet. Not FDA-approved; expected 2027.
See the full Retatrutide review for dosing, efficacy data, side effects, and the full pharmacy + telehealth program comparison.
Insurance coverage for Retatrutide in Pennsylvania
Pennsylvania Medical Assistance ended GLP-1 coverage for weight loss on January 1, 2026, after covering it since January 2023. GLP-1s for other indications are still covered with prior authorization.
We do not track carrier-level coverage for Retatrutide. Check your plan's formulary or our insurance hub.
Telehealth and prescribing in Pennsylvania
A telehealth clinician must be licensed in Pennsylvania to prescribe Retatrutide to you while you are in Pennsylvania.
Platforms differ in which drugs they prescribe, insurance handling, and clinical model. See our platform comparisons.
Compounded retatrutide
On April 30, 2026, FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list, which would stop outsourcing facilities from compounding them from bulk ingredients. The comment period was extended to July 30, 2026. As of September 15, 2026, no final decision has been published. The proposal does not address 503A compounding for an individual patient's documented clinical need.
Retatrutide in Pennsylvania: common questions
Is Retatrutide legal in Pennsylvania?+
Yes. Retatrutide (retatrutide) is FDA-approved and legal in all 50 US states including Pennsylvania. State-level differences appear in Medicaid coverage and clinician licensing, not in the legality of the medication itself.
Can I get Retatrutide via telehealth in Pennsylvania?+
Yes, from a clinician licensed in Pennsylvania. A telehealth clinician must be licensed in Pennsylvania to prescribe Retatrutide to you while you are in Pennsylvania.
Does Pennsylvania Medicaid cover Retatrutide?+
Not covered for weight loss. Pennsylvania Medical Assistance ended GLP-1 coverage for weight loss on January 1, 2026, after covering it since January 2023. GLP-1s for other indications are still covered with prior authorization.
What's the cheapest way to get Retatrutide in Pennsylvania?+
The main paths are insurance with prior authorization if your plan covers it, manufacturer cash-pay programs, or telehealth programs that include the medication. NovoCare Pharmacy sells Wegovy pens to cash-pay patients for $349 a month ($199 a month for the first two months for new patients through December 31, 2026). LillyDirect sells Zepbound vials for $299 (2.5 mg), $399 (5 mg), and $449 (7.5 to 15 mg) a month when refilled on time.
Is compounded Retatrutide still available in Pennsylvania?+
Compounding rules are federal, not set by Pennsylvania. On April 30, 2026, FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list, which would stop outsourcing facilities from compounding them from bulk ingredients. The comment period was extended to July 30, 2026. As of September 15, 2026, no final decision has been published. The proposal does not address 503A compounding for an individual patient's documented clinical need.